LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

Home・Elenco Azioni・Erasca Inc

Erasca Inc

Chiusa

13.49 -2.32

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

13.36

Massimo

14.51

Metriche Chiave
By Trading Economics
Entrata	-154M -183M
EPS	-0.6
Dipendenti	103
EBITDA	-5.3M -37M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+57.87% upside

Dividendi
By Dow Jones
Utili prossimi	10 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	1.1B 4.3B
Apertura precedente	15.81
Chiusura precedente	13.49

Erasca Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

2 giu 2026, 20:30 UTC

Utili

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

2 giu 2026, 23:58 UTC

Discorsi di Mercato

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2 giu 2026, 23:46 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

2 giu 2026, 23:46 UTC

Discorsi di Mercato

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2 giu 2026, 23:41 UTC

Discorsi di Mercato

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2 giu 2026, 23:01 UTC

Acquisizioni, Fusioni, Takeovers

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2 giu 2026, 23:01 UTC

Acquisizioni, Fusioni, Takeovers

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2 giu 2026, 23:00 UTC

Acquisizioni, Fusioni, Takeovers

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2 giu 2026, 22:57 UTC

Discorsi di Mercato

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2 giu 2026, 22:50 UTC

Discorsi di Mercato

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2 giu 2026, 21:07 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

2 giu 2026, 21:07 UTC

Discorsi di Mercato

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2 giu 2026, 21:00 UTC

Utili

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 giu 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

2 giu 2026, 20:46 UTC

Utili

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 giu 2026, 20:38 UTC

Utili

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2 giu 2026, 20:21 UTC

Utili

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 giu 2026, 20:12 UTC

Utili

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks 3Q Product Rev $594M

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks Raises FY26 View To Rev $11.415B-$11.425B >PANW

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks 3Q Remaining Performance Obligation $18.4B

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks 3Q Adj EPS 85c >PANW

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks 3Q Loss $177M >PANW

Confronto tra pari

Modifica del prezzo

Erasca Inc Previsione

Obiettivo di Prezzo

By TipRanks

57.87% in crescita

Previsioni per 12 mesi

Media 20.27 USD 57.87%

Alto 30 USD

Basso 9 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Erasca Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

11 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 11 che hanno fornito valutazioni azionarie a Erasca Inc - Dist negli ultimi 3 mesi.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.